TERIPARATIDE DB06285 C181H291N55O51S kDa CATEGORY

Slides:



Advertisements
Similar presentations
Treatment. Bisphosphonates Promotes bone formation and decreases bone resorption Mechanism of Action First line treatment for osteoporosis in both men.
Advertisements

Copyright © 2013, 2010 by Saunders, an imprint of Elsevier Inc. Chapter 75 Drugs Affecting Calcium Levels and Bone Mineralization.
Pharmacology of drugs used in calcium & vitamin D disorders
Pharmacology of drugs used in calcium & vitamin D disorders
Pharmacology of drugs used in calcium & vitamin D disorders
Bone Health & Nutrients Chapter 11 – HLTH 120N. What do you know about your bones?  What is peak bone density?  At about what age do you reach it? 
Pharmacology I Session One Pharmacological Principles.
Denileukin diftitox Drugbank ID : DB00004 Chemical formula :
Follitropin beta (DB00066) Approved Drug
Omalizumab Drugbank ID : DB00043
Menotropins Drugbank ID : DB00032
DB05829 PREOTACT C845H1343N223O243S kDa.
Brodalumab Drugbank ID : DB11776 Molecular Weight (Daltons) :144,000
Darbepoetin alfa Drugbank ID : DB
Oprelvekin Drugbank ID : DB00038
FILGRASTIM C845H1343N223O243S kDa ID DB00099 GROUP
Peginterferon alfa-2a Drugbank ID : DB00008
Reteplase Drugbank ID : DB00015
Serum albumin Albunex Optison™ IV infusion
Pramlintide (Approved investigational) DB01278
Dulaglutide Drugbank ID : DB09045.
Epoetin alfa Drugbank ID : DB00016
Elotuzumab Drugbank ID : DB06317.
TALIGLUCERASE ALFA DB08876 C2580H3918N680O727S g/mol
Subcutaneous injection
Pegloticase Protein chemical formula : C1549H2430N408O448S8
Rachel Kim, PharmD Candidate Cone Health Family Medicine
ID DB08935 OBINUTUZUMAB C6512H10060N1712O2020S kDa CATEGORY
ID DB06655 LIRAGLUTIDE C172H265N43O Da.
Albiglutide Drugbank ID : DB09043.
Pegvisomant(DB00082) Approved Drug
Human Serum Albumin (DB00062) Approved Drug
Metreleptin Drugbank ID :DB09046
DB06643 Denosumab C6404H9912N1724O2004S kDa CATEGORY
Peginterferon beta-1a Drugbank ID :DB00060
Asfotase Alfa Drugbank ID : DB09105.
Insulin Degludec Drugbank ID :DB09564
ID DB08898 GLUCARPIDASE C1950H3157N543O599S7 CATEGORY Enzymes.
Salmon Calcitonin Drugbank ID : DB00017
RAXIBACUMAB DB08902 C6320H9794N1702O1998S kDa CATEGORY
DB08879 BELIMUMAB C 6358 H 9904 N 1728 O 2010 S kDa CATEGORY Monoclonal antibodies.
Drugs Affecting Calcium Levels and Bone Mineralization
Romiplostim(DB05332) Approved Drug
Evolocumab Drugbank ID : DB09303.
Peginterferon alfa-2b Drugbank ID : DB00022
Pembrolizumab Drugbank ID :DB09037 Half life : 28 days.
Leuprolide Drugbank ID : DB00007
Natalizumab (Approved, Investigational)
Cetuximab Drugbank ID : DB00002
Interferon alfacon-1 (DB00069) Approved Drug
Pegfilgrastim Drugbank ID : DB00019
Imiglucerase Protein chemical formula : C2532H3854N672O711S16
Anakinra Drugbank ID : DB00026
DB08869 TESAMORELIN C221H366N72O67S • xC2H4O2 where x averages 7.4 acetate counter ions per peptide molecule Daltons (base free)
Ofatumumab Drugbank ID : DB06650 Molecular Weight (Daltons) :146100
Galsulfase (Approved investigational) DB01279
Idarucizumab Molecular Weight (Daltons) : 47766
DB08914 OCRIPLASMIN C1214H1890N338O348S kDa CATEGORY
Sebelipase alfa Protein chemical formula : C1968H2945N507O551S15
Chorionic Gonadotropin (Recombinant)
Chapter 1 Introduction to Biopharmaceutics & Pharmacokinetics
Buy Fosamax - Get Relief from Bone Disease
Medication for osteoporosis
Thyrotropin Alfa Drugbank ID : DB00024
Pegademase bovine Drugbank ID : DB00061
Ixekizumab Drugbank ID : DB11569 Molecular Weight (Daltons) :146,158
Chorionic Gonadotropin (Human)
ID DB06720 VELAGLUCERASE ALFA CATEGORY Enzymes.
1/3/2019 OSTEOPOROSIS.
Basic Biopharmaceutics
Presentation transcript:

TERIPARATIDE DB06285 C181H291N55O51S2 4.12 kDa CATEGORY Bone Density Conservation Agents

DESCRIPTION Teriparatide (recombinant human parathyroid hormone) is a potent anabolic agent used in the treatment of osteoporosis. It is manufactured and marketed by Eli Lilly and Company. INDICATION For the treatment of osteoporosis in men and postmenopausal women who are at high risk for having a fracture. Also used to increase bone mass in men with primary or hypogonadal osteoporosis who are at high risk for fracture. PHARMACODYNAMICS Clinical trials indicate that teriparatide increases predominantly trabecular bone in the lumbar spine and femoral neck; it has less significant effects at cortical sites. The combination of teriparatide with antiresorptive agents is not more effective than teriparatide monotherapy. The most common adverse effects associated with teriparatide include injection-site pain, nausea, headaches, leg cramps, and dizziness. After a maximum of two years of teriparatide therapy, the drug should be discontinued and antiresorptive therapy begun to maintain bone mineral density.

MECHANISM OF ACTION Teriparatide is the portion of human parathyroid hormone (PTH),amino acid sequence 1 through 34 of the complete molecule which contains amino acid sequence 1 to 84. TOXICITY Effects of overexposure may include headaches, dizziness, dizziness, decreased blood pressured, decreased fetal survival, leg cramps, changes in clinical chemistry including increased in blood levels of calcium, decreased serum phosphorous, and increased urinary calcium and phosphorus. METABOLISM Hepatic ABSORPTION Bioavailability is 95% following subcutaneous injection.

ROUTE OF ELIMINATION Peripheral metabolism of PTH is believed to occur by non-specific enzymatic mechanisms in the liver followed by excretion via the kidneys. The 24-hour urine excretion of calcium was reduced by a clinically unimportant amount (15%). VOLUME OF DISTRIBUTION = 0.12 L/kg CLEARANCE = 62 L/hr [Women] 94 L/hr [Men]

SEQUENCE Parathyroid hormone precursor - Homo sapiens (1-34)SVSEIQLMHNLGKHLNSMERVEWLRKKLQDVHNF TARGETS Parathyroid hormone/parathyroid hormone-related peptide receptor

Forteo/Forsteo IV and SC FORTEO (teriparatide [rDNA origin] injection) contains recombinant human parathyroid hormone (1-34), and is also called rhPTH (1-34). It has an identical sequence to the 34 N-terminal amino acids (the biologically active region) of the 84-amino acid human parathyroid hormone. DOSAGE: 20 mcg subcutaneously once a day.

FORMULATION FORTEO is supplied as a sterile, colorless, clear, isotonic solution in a glass cartridge which is pre-assembled into a disposable delivery device (pen) for subcutaneous injection. Each prefilled delivery device is filled with 2.7 mL to deliver 2.4 mL. Each mL contains 250 mcg teriparatide (corrected for acetate, chloride, and water content), 0.41 mg glacial acetic acid, 0.1 mg sodium acetate (anhydrous), 45.4 mg mannitol, 3 mg Metacresol, and Water for Injection. In addition, hydrochloric acid solution 10% and/or sodium hydroxide solution 10% may have been added to adjust the product to pH 4. HALF-LIFE: 5 min (IV) and 1 h (subcutaneous) CLEARANCE: 62 L/h (women) and 94 L/h (men)

ADVERSE REACTION: Feeling light-headed or fainting every time you inject this medicine; fast or pounding heartbeats every time you inject this medicine; or nausea, vomiting, constipation, and muscle weakness. PATENT Country Patent Number Approved Expires (estimated) Canada 2314313 2005-02-08 2018-12-08 Canada 2325371 2004-08-17 2019-08-19 United States 6977077 1999-08-19 2019-08-19 United States 6770623 1998-12-08 2018-12-08

REFERENCE Stroup J, Kane MP, Abu-Baker AM: Teriparatide in the treatment of osteoporosis. Am J Health Syst Pharm. 2008 Mar 15;65(6):532-9. Pubmed Close P, Neuprez A, Reginster JY: Developments in the pharmacotherapeutic management of osteoporosis. Expert Opin Pharmacother. 2006 Aug;7(12):1603-15. Pubmed Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5